Acrux Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Michael Kotsanis

Chief executive officer

AU$710.2k

Total compensation

CEO salary percentage	65.2%
CEO tenure	9.5yrs
CEO ownership	0.5%
Management average tenure	no data
Board average tenure	9.5yrs

Recent management updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

Recent updates

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Nov 16

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

Nov 16

CEO Compensation Analysis

How has Michael Kotsanis's remuneration changed compared to Acrux's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	-AU$709k
Sep 30 2023	n/a	n/a	-AU$736k
Jun 30 2023	AU$710k	AU$463k	-AU$764k
Mar 31 2023	n/a	n/a	-AU$4m
Dec 31 2022	n/a	n/a	-AU$8m
Sep 30 2022	n/a	n/a	-AU$9m
Jun 30 2022	AU$670k	AU$446k	-AU$10m
Mar 31 2022	n/a	n/a	-AU$10m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$11m
Jun 30 2021	AU$645k	AU$468k	-AU$13m
Mar 31 2021	n/a	n/a	-AU$12m
Dec 31 2020	n/a	n/a	-AU$11m
Sep 30 2020	n/a	n/a	-AU$10m
Jun 30 2020	AU$510k	AU$452k	-AU$9m
Mar 31 2020	n/a	n/a	-AU$10m
Dec 31 2019	n/a	n/a	-AU$11m
Sep 30 2019	n/a	n/a	-AU$10m
Jun 30 2019	AU$521k	AU$451k	-AU$8m
Mar 31 2019	n/a	n/a	-AU$9m
Dec 31 2018	n/a	n/a	-AU$9m
Sep 30 2018	n/a	n/a	-AU$12m
Jun 30 2018	AU$690k	AU$406k	-AU$14m
Mar 31 2018	n/a	n/a	-AU$15m
Dec 31 2017	n/a	n/a	-AU$15m
Sep 30 2017	n/a	n/a	-AU$8m
Jun 30 2017	AU$702k	AU$400k	-AU$243k

Compensation vs Market: Michael's total compensation ($USD469.61K) is above average for companies of similar size in the Australian market ($USD296.74K).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Kotsanis (57 yo)

9.5yrs

Tenure

AU$710,238

Compensation

Mr. Michael John Kotsanis, BSc, GradDipBus, MBus has been Chief Executive Officer and Managing Director of Acrux Limited since November 03, 2014. He served as an Independent Non-Executive Director at IDT A...

Board Members

Name	Position	Tenure	Compensation	Ownership
Michael Kotsanis	CEO, MD & Executive Director	9.5yrs	AU$710.24k	0.52% A$ 98.2k
Geoffrey Edward Brooke	Independent Non-Executive Director	7.9yrs	AU$69.23k	0.58% A$ 109.9k
Ross Dobinson	Independent Non-Executive Chairman	26.2yrs	AU$100.32k	1.81% A$ 341.2k
Timothy Oldham	Independent Non-Executive Director	10.6yrs	AU$67.70k	0.52% A$ 98.8k
Donald Brumley	Independent Non-Executive Director	2.9yrs	AU$76.82k	1.17% A$ 220.7k

9.5yrs

Average Tenure

67yo

Average Age

Experienced Board: ACR's board of directors are considered experienced (9.5 years average tenure).

Acrux Management

Management criteria checks 1/4

Key information

Recent management updates

Acrux Limited, Annual General Meeting, Nov 29, 2023

Independent Non-Executive Director recently bought AU$92k worth of stock

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

Recent updates

First half 2024 earnings released: AU$0.011 loss per share (vs AU$0.011 loss in 1H 2023)

Acrux Limited to Report First Half, 2024 Results on Feb 23, 2024

Acrux Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.035 loss in FY 2022)

New minor risk - Financial data availability

New minor risk - Share price stability

Independent Non-Executive Director recently bought AU$92k worth of stock

First half 2023 earnings released: AU$0.011 loss per share (vs AU$0.019 loss in 1H 2022)

Acrux and Padagis Announce the Launch of Prilocaine and Lidocaine Cream in the United States

Here's Why Shareholders May Want To Be Cautious With Increasing Acrux Limited's (ASX:ACR) CEO Pay Packet

Acrux Limited, Annual General Meeting, Nov 23, 2022

Full year 2022 earnings released: AU$0.035 loss per share (vs AU$0.057 loss in FY 2021)

Acrux's Sixth Generic Dossier Accepted by FDA for Review

Less than half of directors are independent

Non-Executive Director recently bought AU$89k worth of stock

It's Unlikely That Acrux Limited's (ASX:ACR) CEO Will See A Huge Pay Rise This Year

We Think Acrux (ASX:ACR) Needs To Drive Business Growth Carefully

Acrux Limited Announces Fifth Generic Dossier Accepted by FDA for Review

Acrux Limited Launches Testosterone Topical Solution USP, 30mg Per Actuation

Full year 2021 earnings released: AU$0.057 loss per share (vs AU$0.056 loss in FY 2020)

CFO & Company Secretary Deborah Ambrosini has left the company

Acrux Receives Approval from the FDA for Its Generic Version of Jublia

Non Executive Director Norman Gray has left the company

Acrux Confirms Patent Challenge

Here's Why We're Watching Acrux's (ASX:ACR) Cash Burn Situation

Is Acrux (ASX:ACR) In A Good Position To Invest In Growth?

Acrux Limited Announces the US Food and Drug Administration Approves its Generic Product Based on Perrigo's Testosterone Topical Solution, 30mg/1.5mL

New 90-day high: AU$0.21

Acrux Limited announced that it expects to receive AUD 7.815143 million in funding from Bioscience Managers Pty Ltd and other investors

Here's What We Think About Acrux's (ASX:ACR) CEO Pay

Acrux Limited Signs Licensing Agreement with Dash Pharmaceuticals

Full year earnings released - AU$0.057 loss per share

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members

Average Tenure

Average Age